Replimune (REPL) stock plunges as the company seeks layoffs following the FDA rejection of its cancer drug RP1 for melanoma.

As climate change outpaces ecosystems' abilities to adapt, scientists are turning to conservation genomics, but experts ...

Court of King’s Bench Justice puts legal pause on the certification until she makes a ruling on the case brought forward by ...